Professional Documents
Culture Documents
Introduction
Since May 2022, the Centers for Disease Control and Prevention has been tracking cases of
Monkeypox virus infection in 47 states, Washington, D.C., and Puerto Rico. More than 28,000
cases in 88 countries have been confirmed globally, with 27,875 cases occurring in countries that
have not historically reported monkeypox. Although data are limited, pregnant or breastfeeding
people may be at heightened risk for worsened disease severity and adverse perinatal outcomes
associated with monkeypox infection. This document complements the rapidly evolving
guidance from the Centers for Disease Control and Prevention, focusing on unique maternal,
fetal, and perinatal clinical considerations.
Human-to-human transmission occurs from (1) direct contact with an infected rash, scab, or
body fluid; (2) respiratory secretions during prolonged or intimate physical contact; and (3)
contact with contaminated items, such as clothing or bedding. A person with monkeypox
infection is considered contagious from initial viral prodrome and develop of rash until the
lesions have fully healed and new skin has formed over the scabs. It is not clear whether
asymptomatic spread occurs, nor is it clear if transmission can also occur through vaginal or
seminal fluids. Perinatal infection can occur through transplacental transmission or during close
contact during and after birth.
Zoonotic (animal-to-human) transmission also occurs following direct contact with the blood,
bodily fluids, or cutaneous or mucosal lesions of infected animals.
Data regarding risk factors for infection and disease progression in this outbreak are informed
from a recent case series of 528 laboratory-confirmed infections diagnosed between April 27 and
June 24, 2022, at 43 sites in 16 countries. Among the group, 13% required hospital admission for
pain and symptom control, including severe pain, severe pharyngitis limiting oral intake, acute
kidney injury, and myocarditis, and 5% of the total cohort received monkeypox-specific
treatment. No deaths occurred.
Monkeypox virus can be transmitted to the fetus during pregnancy or to the newborn by close
contact during and after birth. A commentary examined 5 cases with documented perinatal
outcomes reported in the literature. Among these 5 cases, 2 resulted in spontaneous abortion, 1
resulted in stillbirth, and 1 resulted in the preterm birth of a neonate with congenital monkeypox
infection and subsequent neonatal death. Other individual contributing circumstances are not
known. The frequency and risk factors for disease severity and adverse pregnancy outcomes are
also unknown.
Additionally, clinicians should use appropriate infection prevention measures when collecting
specimens for monkeypox evaluation. These measures include the use of personal protective
equipment such as eye protection, gown, gloves, and a particulate respirator approved by the
National Institute for Occupational Safety and Health (NIOSH), e.g. N95.
There are no specific treatments for monkeypox virus infection. Two antivirals and vaccinia
immune globulin are available from the Strategic National Stockpile under expanded access
investigational new drug protocols held by the Centers for Disease Control and Prevention. The
risks and benefits of treatment should be discussed with the patient using shared decision-
making.
Most people with infection have a mild, self-limiting illness. Severe disease includes
hemorrhagic disease, sepsis, encephalitis, or other conditions requiring hospitalization.
Persons with monkeypox infection should also be counseled to isolate for the duration of the
illness. The decision to treat and monitor a pregnant person as an outpatient or inpatient should
be individualized. As CDC recommends, if treatment is indicated, tecovirimat should be
considered the first-line antiviral drug for pregnant, recently pregnant, and breastfeeding people
(see Table).
Table. Drugs Used for Treatment of Monkeypox
Pregnancy Breastfeeding
Drug Availability Administration
data data
Tecovirimat Limited to Weight-based Pregnant Breastfeeding
(TPOXX, health patients not patients not
ST-246) department/CDC Intravenous and included in included in
expanded access oral pharmacokinetic pharmacokinetic
protocol studies studies
No
contraindications
in manufacturer
labeling
Vaccinia Limited to Intravenous No human or No human or
intravenous health animal data animal data
immune department/CDC
globulin expanded access Immune Immune
(VIGIV) protocol globulins globulins
known to cross known to cross
the placenta the placenta
without severe without severe
adverse effects adverse effects
CDC, Centers for Disease Control and Prevention; Cr, creatinine; CrCl, creatine clearance
Vaccines against monkeypox and administration during pregnancy
Two vaccines directed against monkeypox are currently available. ACAM2000 is a replicating
viral vaccine licensed for the prevention of smallpox. It is contraindicated in pregnant or
breastfeeding people due to the risk of pregnancy loss, congenital defects, and vaccinia virus
infection.
JYNNEOS is a live, nonreplicating viral vaccine licensed for the prevention of both smallpox
and monkeypox disease. Available human data on JYNNEOS administered to pregnant people
are insufficient to determine if there are any vaccine-associated pregnancy-specific benefits or
risks. Animal studies have not shown evidence of harm, and the vaccine should not be withheld
from pregnant individuals who otherwise would be eligible in the context of shared decision-
making. The JYNNEOS vaccine requires two doses administered 28 days apart for maximum
effectiveness. Currently, JYNNEOS is in limited supply and available to individuals through
state health departments who meet the following criteria:
• Postexposure prophylaxis either within 4 days of a known exposure to monkeypox to reduce
the likelihood of infection or between 4 and 14 days postexposure which may reduce the
severity of symptoms
• Known contacts of monkeypox cases identified by public health via case investigation,
contact tracing, and risk exposure assessments (may include sexual partners, household
contacts, and healthcare workers)
• Presumed contacts who meet the following criteria:
Know that a sexual partner in the past 14 days was diagnosed with monkeypox; or
Had multiple sexual partners in the past 14 days in a jurisdiction with known monkeypox
Coadministration with other vaccines: JYNNEOS typically may be given at the same time as
other vaccines. However, because of the observed risk for myocarditis after receipt of
ACAM2000 vaccine and mRNA and Novavax COVID-19 vaccines and the unknown risk for
myocarditis after JYNNEOS, some people might consider waiting 4 weeks after JYNNEOS or
ACAM2000 before receiving a Moderna, Novavax, or Pfizer-BioNTech COVID-19 vaccine. If
an orthopoxvirus vaccine is recommended for prophylaxis in the setting of an outbreak,
orthopoxvirus vaccination should not be delayed because of recent receipt of a Moderna,
Novavax, or Pfizer-BioNTech COVID-19 vaccine; no minimum interval between COVID-19
vaccination with these vaccines and orthopoxvirus vaccination is necessary (CDC Monkeypox
Vaccination).
Currently, in the absence of obstetric indications, SMFM does not recommend preterm or early
term delivery. Decisions regarding the mode of delivery should be individualized. Cesarean
delivery can be considered if lesions are present and cannot be covered in or near the vaginal,
anal, or perineal regions to reduce the risk of neonatal contact during delivery. However, the
guidance will continue to evolve as pregnancy-specific data emerge.
See CDC and AAP for additional information on infant feeding with breastmilk.
Infection Control
Infection control practices for the care of patients who are pregnant with monkeypox infection
are the same as those for patients who are not pregnant with monkeypox infection – including
appropriate isolation of patients with monkeypox; training for healthcare personnel on maternity
and newborn care units on correct adherence to infection control practices and PPE (gown,
gloves, eye protection, and NIOSH-approved particulate respirator equipped with an N95 filter
or higher) use and handling; and ensuring sufficient and appropriate PPE supplies are positioned
at all points of care.
Further, visitors to pregnant or postpartum patients with monkeypox should be limited to those
essential to the patient’s care and wellbeing. The use of alternative mechanisms for patient and
visitor interactions, such as video-call applications, should be encouraged for any additional
support.
Further resources:
CDC: https://www.cdc.gov/poxvirus/monkeypox/index.html
ACOG: https://www.acog.org/clinical-information/physician-faqs/obstetric-care-considerations-
monkeypox
Suggested Citation: Society for Maternal-Fetal Medicine (SMFM). Monkeypox and Pregnancy: What
Maternal-Fetal Medicine Subspecialists Need to Know. Washington, DC: SMFM; 2022. Available at:
https://www.smfm.org/monkeypox. Retrieved [enter date].